Academia Sinica

Chang Gung Memorial Hospital

The Scripps Research Institute

Development Center for Biotechnology

Dcb-usa LLC

John Yu

Alice L Yu

Chi-Huey Wong

Chung-Yi Wu

Sheng-Hung Wang

Han-Chung Wu

I-Ju Chen

Yi-Chang Chen

Kuo-I Lin

Wen-Bin Yang

Ying-Yung Lok

Chuan-Lung Hsu

Mei-Ying Liao

Hung-Chih Kuo

Ruei-Min Lu

H C Wu

Tung-Ying Lu

Cheng-Fu Kao

Ya-Hui Wang

Ming-Wei Kuo

Jui-Chin Chang

An isolated cancer-targeting peptide that includes at least two copies of the amino acid sequence PFLP (SEQ ID NO: 1) or PFLF (SEQ ID NO: 2). Also disclosed is a pharmaceutical composition for treating cancer. The composition contains the isolated cancer-targeting peptide and an anti-cancer agent. Further disclosed is a bispecific anti-cancer antibody that includes the isolated cancer-targeting peptide and an antigen-binding peptide that stimulates T cell activity. Methods are provided for treating cancer by administering the pharmaceutical composition or the bispecific anti-cancer antibody. Further provided is a method for diagnosing cancer by administering a radionuclide-labeled cancer-targeting peptide to an individual and imaging a location of the radionuclide.

Tandem repeat cancer-targeting peptides for molecular conjugation or engineering and uses thereof in cancer theranostics

An immunogenic composition containing a glycan conjugate including a carrier protein, and a glycan including Globo H, an immunogenic fragment thereof, or stage-specific embryonic antigen-4 (SSEA-4), wherein the glycan is conjugated with the carrier protein through a linker.

Globo H and related anti-cancer vaccines with novel glycolipid adjuvants

A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane and coiled-coil domains protein 3 (TMCC3), wherein the antibody binds to an epitope in an extracellular domain of TMCC3. The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane and coiled-coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample.

Methods for suppressing cancer by inhibition of TMCC3

Methods and compositions for treating retinal diseases comprising therapeutic amounts of a compound selected from a normal Puf-A gene product, an active polypeptide fragment thereof, an analog thereof or a peptidomimetic thereof. Vectors, including AAV vectors comprising the therapeutic compound are provided. Puf-A compositions suitable for subretinal, intravitreal, topical, subconjunctival, retrobulbar, periocular, suprachoroidal, or intraocular administration are provided. Methods for screening siRNA, RNAi and shRNA, small molecules and monoclonal antibodies that inhibit Puf-A target activity and reduce apoptosis are provided.

Puf-A and related compounds for treatment of retinopathies and sight-threatening ophthalmologic disorders

Methods are disclosed which are useful in increasing maturation of dendritic cells from CD14mononuclear cells, by contact with a composition comprising a fucose-containing glycoprotein fraction from. The extract can also be used for increasing production of a cytokine or a chemokine in a dendritic cell or CD19B cell. In addition, a fucose-containing glycoprotein fraction fromcan be administered to a subject identified as needing increased immunoglobulin, cytokine, or chemokine production.

Fungal immunostimulatory compositions

Cancer-targeting peptides having a PXLXmotif, in which Xis His or an amino acid residue with a hydrophobic side chain and Xis Pro, Phe, or Trp. Also disclosed herein are conjugates containing the cancer-targeting peptides and uses thereof in cancer treatment and diagnosis.

Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis

Methods are provided for inducing non-pluripotent cells to become pluripotent. Methods also include identifying and isolating induced pluripotent (iPS) cells and uses thereof. Compositions and kits for carrying out the subject methods are also provided.

EpCAM as a reprogramming factor for non-pluripotent cells

Immunogenic compositions, cancer vaccines and methods for treating cancer are provided. Compositions comprising: (a) a glycan such as Globo H or an immunogenic fragment thereof, wherein the glycan is conjugated with a carrier protein by a linker such as para-nitrophenyl; and (b) an adjuvant comprising glycolipid capable of binding CD1d on a dendritic cell, such as an &#x3b1;-galactosyl-ceramide derivative, wherein the immunogenic composition induces an immune response that induces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies, are provided. Immunogenic compositions comprising the carrier protein diphtheria toxin cross-reacting material 197 (DT-CRM197) and the adjuvant C34 are provided. Antibodies generated by immunogenic compositions disclosed herein further neutralize at least one of the antigens Globo H, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4). Therapeutics against breast cancer stem cells comprising immunogenic compositions comprising Globo H, SSEA-3 or SSEA-4 conjugated with DT-CRM197.

The present invention provides a process for making an in vivo model of human leukemia. The process includes the steps of: pre-conditioning an immunodeficient rodent by administering to the rodent a sub-lethal dose of irradiation and injecting the rodent with an effective pre-conditioning amount of human fetal cord blood mononuclear cells; maintaining the rodent for from about 5 to 10 days; and injecting the rodent with an effective engrafting amount of primary human leukemia cells. An in vivo and in vitro model of human leukemia are also provided.

Growing community of inventors

Taipei, Taiwan

John Yu